Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

The Crime Branch of Delhi Police has busted a racket selling spurious cancer medicines and injections, arresting six ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking ...

The accused individuals were selling spurious cancer medicines and injections, including Opdivo, Pembrolizumab Injection, Keytruda, and others, without proper authorisation. The police raided three ...